Clinical Trial Update: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization [Phase 4]

View source ↗

Summary

Phase 4 trial update on dosing strategy for intravitreal ranibizumab in choroidal neovascularization associated with pathological myopia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Pathological Myopia

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University | Conditions: Choroidal Neovascularization | Phase 4 | Status: COMPLETED